Allogene Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALLO Nasdaq 2830 allogene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allogene Therapeutics, Inc.

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report? - Jun 12th, 2026 9:30 am
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio - Jun 7th, 2026 11:57 am
Allogene Therapeutics Announces Planned CEO Succession - May 28th, 2026 3:02 pm
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - May 26th, 2026 6:30 am
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1 - May 14th, 2026 8:17 am
Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders - May 14th, 2026 7:20 am
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ... - May 13th, 2026 11:00 pm
Allogene Therapeutics Q1 Earnings Call Highlights - May 13th, 2026 6:13 pm
Allogene Therapeutics Q1 2026 Earnings Call Transcript - May 13th, 2026 4:12 pm
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update - May 13th, 2026 2:02 pm
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update - May 6th, 2026 6:30 am
William Blair Initiates Natera (NTRA) With Outperform - May 2nd, 2026 8:35 am
Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock - May 1st, 2026 3:23 am
Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In - Apr 25th, 2026 3:06 pm
H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO) - Apr 23rd, 2026 1:30 am
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - Apr 21st, 2026 6:30 am
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - Apr 20th, 2026 6:30 am
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - Apr 16th, 2026 2:01 pm
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? - Apr 15th, 2026 3:04 pm
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases - Apr 15th, 2026 6:30 am